FDA has also warned that poor compounding practices can create contamination or potency problems, although that concern applies to compounded drugs generally rather than proving that every compounded GLP-1 product is contaminated
Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
Join us at our free digital summit to hear from leading experts, brands and researchers tackling the big questions: What role can food play in supporting GLP-1 users
Nausea was reported in approximately 4060% of participants in the mid-to-high dose groups (8 mg and 12 mg), with lower rates observed in participants receiving the smallest doses or following slower titration schedules
These include: A new or persistent lump or swelling in the neck, particularly in the thyroid region Progressive difficulty swallowing (dysphagia) or a sensation of pressure in the throat Persistent hoarseness or voice changes lasting more than three weeks Unexplained stridor (high-pitched breathing sound) Rapidly enlarging neck mass Patients experiencing any of these symptoms should contact their GP promptly for clinical assessment, in line with NICE guidance on suspected cancer referral (NG12)